Skip to Content

Ampio Pharmaceuticals Inc AMPE

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Ampio Pharmaceuticals Inc is a biopharmaceutical company. The company focused primarily on developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process and decreasing vascular permeability. Ampio's leading product candidates are Ampion and Optina. It is currently conducting the second pivotal clinical trial in the United States for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee.

Contact
373 Inverness Parkway, Suite 200
Englewood, CO, 80112
T +1 720 437-6500
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type Distressed
Employees 23